Supplementary Material on Treating Spondyloarthropathies to Target A Systematic Literature Review Supporting Treatment Recommendations

Transcription

1 Supplementary Material on Treating Spondyloarthropathies to Target A Systematic Literature Review Supporting Treatment Recommendations including Supplementary Tables S1 (Search terms) and S2 (Studies, inclusion criteria at enrollment, patients baseline disease activity) Table S1. Search terms 1 (treat$ adj4 target$).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier] 2 (titrat$ or adjust$ or response-based).mp. 3 (optim$ or adapt$ or switch$ or add$ or chang$ or expand$ or step$ or combin$ or intensif$ or escalat$).ti. 4 ((strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or control$) adj2 (treat$ or therap$)).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier] 5 (lack$ and effic$).mp. or (insuffi$ and respon$).m_titl. [mp=ps, rs, ti, ot, ab, nm, hw, ui, an, sh, tn, dm, mf, dv, kw] 6 demand.m_titl. or demand.mp. or on-demand.mp. 7 ((remission or ((low$ or moderate or medium or high) and activity)) adj3 (strateg$ or optimi$ or adapt$ or control$ or frequency or dose$ or dosing)).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier] 8 *Disease Progression/ or *Disease Management/ or *Disease Outbreaks/ or Disease/ or ((strateg$ or proced$ or consequ$ or therap$ or halt$ or stop$ or revers$ or dela$ or arrest$ or detain$ or slow$ or preven$ or retard$ or avoid$) adj3 (structural or functional or erosi$ or progre$ or disabilit$ or invalidity or impediment or disablement or radiograph$ or radiolog$)).mp. 9 *Remission Induction/ or (strateg$ or aim$ or goal$ or target$ or tight$ or aggressiv$ or intens$ or control$).ti. 10 ankylosing spondylitis.mp. or ankylosing spondylitis/ 11 psoriatic arthritis.mp. or psoriatic arthritis/ 12 spondyl$.m_titl. 13 seronegative.m_titl. 14 (psoriasis or (skin and psoriatic and arthritis) or pasi).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier] 15 (randomized controlled trial or clinical trial).pt. or Double-Blind Method/ or "double blind:".mp. or Placebos/ or placebo:.mp. or random:.mp. or single-blind method/ or exp Clinical Trials/ or clinical trial$.mp. or ((singl$ or doubl$ or trebl$) adj2 (blind$ or mask$)).mp. or placebo$.mp. or exp Research Design/ or comparative study.pt. or exp Evaluation Studies/ or follow-up studies/ or prospective studies/ or (control$ or prospectiv$ or volunteer$).mp. or clinical trial.mp. or Clinical Trial/ or metaanalysis.mp. or Meta-Analysis/

2 Table S2. Studies and their inclusion criteria at enrollment, patient baseline disease activity STUDY / AUTHOR; PY ANKYLOSING SPONDYLITIS INCLUSION CRITERIA BASELINE CHARACTERISTICS DISEASE FUNCTION ACTIVITY BASDAI ADDITIONAL INCLUSION CRITERIA BASDAI BASFI ATLAS at least 2 of 3 clinical criteria: 6.3± ±2.2 BASDAI 4 MST 1 hour VAS total back pain 4 (0-10) ASSERT BASDAI ( ) 5.7 ( ) and VAS spinal pain 4 (0 10) Inman BASDAI ( ) 5.2 ( ) and VAS total back pain 4 (0 10) Haibel ± ±2.0 CANDLE not stated not stated Meric ( ) not stated Jois ( )# 6.4 ( )# Cherouvim BASDAI 3 not stated not stated and pain >3 months with VAS pain 4 on 2 successive occasions Collantes-Estevez not stated - not stated not stated Van Denderen not applicable at least one of four clinical crit. MST>30min Peripheral synovitis Enthesopathy VAS pain>2 plus one laboratory criteria: ESR>20mm/h or CRP>20mg/l 4.4± ±4.1 Darmawan ± ±1.91 Cheung not applicable ( )* 7.0 ( )* 8.5 ( )**p=n.sign. 7.3 ( )**p=n.sign. Breban BASDAI 3 and 1 of the following: 6.2± ±2.0 and VAS axial pain 3 CRP more than twice ULN

3 Braun BASDAI 4 and VAS spinal pain 4 PSORIATIC ARTHRITIS JOINT COUNTS positive MRT of spine or SI joints enthesitis (power Doppler) ADDITIONAL INCLUSION CRITERIA 6.4± ± SWOLLEN & TENDER JOINT COUNTS Cherouvim SJC and not stated not stated 3 TJC Collantes-Estevez not stated not stated not stated not stated ADEPT Kavanaugh IMPACT Feletar SJC and 3 TJC 17 - SJC76: 14.3±12.2 TJC78:23.9± ± SJC and SJC 3 and at least 1 subset of PsA SJC66: 12.0±8.4 not stated 3 TJC and TJC 3 and plaque psoriasis with a lesion TJC68: 22.5±5.7 and negative RF of 2cm Ø 5 SJC and 5 TJC 6 SJC and / or 6 TJC SJC 5 and TJC 5 and either CRP 15mg/l and/or MST 45 min active psoriasis, with at least one plaque 2cm Ø SJC66: 13.9±7.9 TJC68: 24.6± SJC66: 9.1± ±0.6 Rahman not stated - SJC: 15.4±9.1 PSORIASIS INCLUSION CRITERIA PASI Others De Jong Stable psoriasis for 3 months not stated MPSS=2.5 # Beissert PASI ± ±11.1 Nevin not stated $ - *Patients with spinal ankylosis; **patients without spinal ankylosis; Tender (TJC) and Swollen (SJC) are enlisted as specified in the respective manuscript. Where available, the applied number of joints (66 or 68 joint counts, etc) are specified. Mean±SD, median (Interquartilrange), #median (range), or $range are given; Ø=diameter; SI joints=sacroiliac joints; RF=rheumatoid factor; PASI=, MPSS=modified psoriasis severity score - HAQ

4 Bibliography 1. van der Heijde D, Kivitz A, Schiff MH, et al. for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54(7): van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52: Inman RD, Davis JC, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58(11): Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58(7): Inman RD, Maksymowych WP for the CANDLE Study Group. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 2010;37(6): Meric JC, Mulleman D, Ducourau E, et al. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011;33(4): Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis--clinicallyand cost-effective. Rheumatol (Oxford) 2006;45(12): Cherouvim EP, Zintzaras E, Boki KA, et al. Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3mg/kg: A 20-month open treatment. J Clin Rheumatol 2004;10: Collantes-Estevez E, Munoz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicenter study. Rheumatology (Oxford) 2005;44(11): Van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, et al. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J Rheumatol 2003;30(7): Darmawan J, Nasution AR, Chen SL, et al. Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD stage II treatment of the autoimmune diseases. J Rheumatol 2006;33(12): Cheung PPM, Tymms KE, Wilson BJ, et al. Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 2008;38(6):

5 13. Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58(1): Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67(3): Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64: Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68(5): Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52: Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-fourweek efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60(4): Kavanaugh A, Krueger GG, Beutler A, et al. for the IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66(4): Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004;63(2): Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 1998;25(10): De Jong EMGJ, Mork NJ, Seijger MMB, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. British Journal of Dermatology 2003;148: Beissert S, Pauser S, Sticherling M, et al. A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis. Dermatology 2009;219: Nevin RJ, Schulz EJ. Treatement of psoriasis with cyclosporine. South African Medical Journal 1995;85: